CN115989024A - 治疗三叉神经痛的方法 - Google Patents

治疗三叉神经痛的方法 Download PDF

Info

Publication number
CN115989024A
CN115989024A CN202180049062.XA CN202180049062A CN115989024A CN 115989024 A CN115989024 A CN 115989024A CN 202180049062 A CN202180049062 A CN 202180049062A CN 115989024 A CN115989024 A CN 115989024A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049062.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·加里波帝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noema Pharma AG
Original Assignee
Noema Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma AG filed Critical Noema Pharma AG
Publication of CN115989024A publication Critical patent/CN115989024A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN202180049062.XA 2020-07-30 2021-07-30 治疗三叉神经痛的方法 Pending CN115989024A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058630P 2020-07-30 2020-07-30
US63/058630 2020-07-30
PCT/EP2021/071376 WO2022023519A1 (en) 2020-07-30 2021-07-30 Methods of treatment of trigeminal neuralgia

Publications (1)

Publication Number Publication Date
CN115989024A true CN115989024A (zh) 2023-04-18

Family

ID=77520687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049062.XA Pending CN115989024A (zh) 2020-07-30 2021-07-30 治疗三叉神经痛的方法

Country Status (15)

Country Link
US (2) US20230172922A1 (https=)
EP (1) EP4188370A1 (https=)
JP (1) JP2023540849A (https=)
KR (1) KR20230047132A (https=)
CN (1) CN115989024A (https=)
AR (1) AR123108A1 (https=)
AU (1) AU2021316675A1 (https=)
BR (1) BR112023001621A2 (https=)
CA (1) CA3182457A1 (https=)
CL (1) CL2023000261A1 (https=)
IL (1) IL300124A (https=)
MX (1) MX2023001288A (https=)
PH (1) PH12023550204A1 (https=)
TW (1) TW202220649A (https=)
WO (1) WO2022023519A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030559A1 (en) * 2004-06-01 2006-02-09 Bernd Buettelmann Diazole derivatives
US20090239919A1 (en) * 2008-03-08 2009-09-24 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
CN101568531A (zh) * 2006-12-21 2009-10-28 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
WO2011035209A1 (en) * 2009-09-17 2011-03-24 Vanderbilt Universtiy Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030559A1 (en) * 2004-06-01 2006-02-09 Bernd Buettelmann Diazole derivatives
CN101568531A (zh) * 2006-12-21 2009-10-28 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
US20090239919A1 (en) * 2008-03-08 2009-09-24 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
颜耀东: "《缓释控释制剂的设计与开发》", 30 June 2006, 中国医药科技出版社, pages: 287 - 288 *

Also Published As

Publication number Publication date
TW202220649A (zh) 2022-06-01
EP4188370A1 (en) 2023-06-07
AU2021316675A1 (en) 2023-01-19
CL2023000261A1 (es) 2023-09-08
AR123108A1 (es) 2022-10-26
US20230172922A1 (en) 2023-06-08
WO2022023519A1 (en) 2022-02-03
MX2023001288A (es) 2023-04-28
CA3182457A1 (en) 2022-02-03
IL300124A (en) 2023-03-01
PH12023550204A1 (en) 2024-06-24
US20250345320A1 (en) 2025-11-13
BR112023001621A2 (pt) 2023-04-04
KR20230047132A (ko) 2023-04-06
JP2023540849A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
CN108785265B (zh) 杂环化合物和其用途
US20250099445A1 (en) Methods of treatment of tuberous sclerosis complex
CN103833713B (zh) 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
HU199440B (en) Process for producing morpholine derivatives and pharmaceutical compositions comprising the compounds
KR20210028680A (ko) 융합된 트리사이클릭 감마-아미노산 유도체의 조성물 및 이의 제조 방법
CN121891333A (zh) 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途
JP5571072B2 (ja) アルファアドレナリン介在症状の治療方法
CN113214209A (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
JP2020528881A (ja) フェノラミンｇ型結晶、その製造方法並びにその組成物及び用途
CN115989024A (zh) 治疗三叉神经痛的方法
CN109721557B (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
WO2024118936A1 (en) 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies
OA21124A (en) Methods of treatment of trigeminal neuralgia.
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
CN109721558B (zh) 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途
RU2693633C1 (ru) Фармацевтическая композиция для лечения последствий черепно-мозговой травмы и способ её получения (варианты)
CN106491592B (zh) 土木香内酯衍生物及其盐在制备治疗甲状腺炎药物中的应用
CN121226301A (zh) 刺槐素与哌嗪共晶物及制备方法和其组合物与用途
CN103788044B (zh) 硝克柳胺化合物晶i型、其制法和其药物组合物与用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination